In an appeal to the Patent Trial and Appeal Board, biotechnology company Moderna has asked not to review its COVID-19 vaccine patents that are currently being contested by pharmaceutical rivals Pfizer and BioNTech. Moderna posits that a related district court trial is anticipated to conclude before the board could reach a decision and emphasises that the undermining petitions do not demonstrate that the patents are in fact invalid.
These patent disputes lie at the heart of the fierce competition dominating the global pharmaceutical industry in the light of the COVID-19 pandemic, with giants such as Pfizer, BioNTech, and Moderna each striving to protect their innovative work addressing an unprecedented global health crisis. As the dispute unfolds, the involved parties keenly await a definitive ruling, one that could potentially shape the landscape of vaccine development and distribution.
For further details on Moderna’s plea to the Patent Trial and Appeal Board, click here.